| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 51 | 53.6x | 17.8x | Around median | |
Growth | 37 | 13.1% | 7.1% | Bottom tier | |
Quality | 66 | 4.8% | 4.5% | Around median | |
Safety | 57 | 3.5x | 2.6x | Around median | |
Capital Return | 70 | 2.31% | 2.12% | Top tier | |
Momentum | 75 | 16.9% | 2.9% | Top tier | |
Sentiment | 60 | 9 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Becton, Dickinson and Company operates as a focused medical technology company following the separation of its Life Sciences business and its combination with Waters, with operations divided among Medical Essentials, Connected Care, BioPharma Systems, and Interventional. Its revenue is generated from essential care products such as catheters, syringes, and BD Vacutainer tubes; systems and devices such as Alaris, Pyxis Pro, HemoSphere Alta, and Rowa; as well as consumables, drug delivery solutions, PureWick products, vascular products, surgical products, and tissue regeneration products.
In fiscal 2026 Q3, revenue reached $5.0 billion, up 4.4% according to management's presentation and 5.4% according to the news release published on August 6, 2026, while gross profit was $2.3 billion, net income was $377 million, and GAAP earnings per share were $1.37. Adjusted gross margin was 54.3% and adjusted operating margin was 24.9%, down 100 and 130 basis points, respectively, while adjusted earnings per share were $3.23 and grew 4.9%.
Growth was broad-based in fiscal 2026 Q3: Medical Essentials grew 3.2%, Connected Care grew 4.4%, BioPharma Systems grew 5.2%, and Interventional grew 5.5%. Biologics, Advanced Patient Monitoring, PureWick, and advanced tissue regeneration posted double-digit growth, while the difficult comparison for the Alaris capital business and vaccine weakness in China constrained portfolio performance.
The average analyst price target is $186.88, compared with a wide target range of $159 to $210 and a Neutral consensus, reflecting disagreement over how much momentum from the new platforms will translate into sustainable growth and profitability. The average target is below the 52-week high of $193.07, while the highest target exceeds that high, and the 52-week range remains wide at $127.58648 to $193.07 amid a reassessment that combines improving results with the expected pressure from Alaris and margins.
Figures in the text are as of 2026-08-27; the live price is shown at the top of the page.
Fiscal 2026 Q3 revenue reached approximately $5.0 billion, up 4.4% according to management's presentation. Biologics, Advanced Patient Monitoring, PureWick, and advanced tissue regeneration delivered double-digit growth, while more than 90% of the portfolio achieved high-single-digit growth. Share gains in Alaris and BD Vacutainer and strength in Rowa and Peripheral Intervention also supported performance, offset by vaccine pressure in China and the difficult comparison for the Alaris capital business.
The company raised its fiscal 2026 adjusted earnings-per-share range to $12.62–$12.72 following fiscal 2026 Q3 results. It also expects revenue growth near the high end of a low-single-digit range, an adjusted operating margin of approximately 25%, and an adjusted tax rate between 16% and 17%. For fiscal 2027, management described the starting point as low-single-digit growth with modest earnings-per-share leverage due to a negative 200-basis-point impact from the completion of Alaris remediation.
BD had signed approximately 100 agreements across new and biosimilar GLP-1 programs by the August 6, 2026 call. These programs contributed to double-digit growth in biologics and 5.2% growth in BioPharma Systems during fiscal 2026 Q3. EMS also used the Vystra pen to launch a semaglutide treatment in Brazil, and according to management, the pen generates greater value for the company than selling a syringe alone.
Automated analysis for informational purposes only — not investment advice.
GAAP net income was $377 million and earnings per share were $1.37 in fiscal 2026 Q3, compared with a net loss of $311 million in fiscal 2026 Q2. Adjusted earnings per share were $3.23, up 4.9%, but adjusted operating margin declined 130 basis points to 24.9%. During the first nine months of fiscal 2026, free cash flow increased approximately 45% to $1.7 billion.
During fiscal 2026 Q3, BD launched the Liverty TIPS Stent Graft in Europe, targeting an approximately $2 billion global venous market growing at a high-single-digit rate. It also launched the Elyra Thulium Fiber Laser System within an approximately $1.5 billion urology endoscopy market and said the pace of installations accelerated following the launch. In noninvasive monitoring, it made the Acumen IQ Plus Finger Cuff and Smart Pressure Controller with HemoSphere Alta available in the United States and Europe with advanced artificial intelligence features.
The completion of Alaris remediation represents the most immediate growth risk, as management expects a 200-basis-point headwind to fiscal 2027 revenue. Tariffs also reduced fiscal 2026 Q3 margins by approximately 110 basis points, while oil prices could increase the cost of resins and plastic components, which represent approximately 5% of cost of goods sold. Vaccine and China pressures add to these risks, along with a divergent analyst target range of $159 to $210 and a Neutral consensus.
